CD4 and infection: Given the comparable levels of elicited antibodies, and the potential for vaccine-elicited CD4+ T cells both to protect from infection (12) and to serve as targets for infection (13, 14), MVAgp140 and the more generally used gp120 boost immunogens merit further evaluation for advancement to clinical studies.